Nav1.7 and other voltage-gated sodium channels as drug targets for pain relief

Expert Opinion on Therapeutic Targets

Volumn 20, Issue 8, 2016, Pages 975-983

  Emery, Edward C ^a   Luiz, Ana Paula ^a   Wood, John N ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Nav1.7; opioids; pain; SCN9A; sensory neurons

Indexed keywords

ENKEPHALINASE INHIBITOR; NALOXONE; SODIUM CHANNEL BLOCKING AGENT; SODIUM CHANNEL NAV1.7; VOLTAGE GATED SODIUM CHANNEL; ANALGESIC AGENT; NARCOTIC ANALGESIC AGENT; SCN9A PROTEIN, HUMAN;

ANALGESIA; COMBINATION DRUG THERAPY; DRUG TARGETING; GAIN OF FUNCTION MUTATION; GENETIC MANIPULATION; HUMAN; INFLAMMATORY PAIN; LOSS OF FUNCTION MUTATION; NEUROPATHIC PAIN; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; REVIEW; ANIMAL; CHRONIC PAIN; DRUG DESIGN; DRUG EFFECTS; GENETICS; KNOCKOUT MOUSE; METABOLISM; MOLECULARLY TARGETED THERAPY; MOUSE; MUTATION; PATHOLOGY;

ANALGESICS; ANALGESICS, OPIOID; ANIMALS; CHRONIC PAIN; DRUG DESIGN; HUMANS; MICE; MICE, KNOCKOUT; MOLECULAR TARGETED THERAPY; MUTATION; NALOXONE; NAV1.7 VOLTAGE-GATED SODIUM CHANNEL; SODIUM CHANNEL BLOCKERS;

EID: 84963582706     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2016.1162295     Document Type: Review

References (84)

1. M.S.Minett, S.Falk, S.Santana-Varela, et al. Pain without nociceptors? Nav1.7-independent pain mechanisms. Cell Rep. 2014;6(2):301–12.
2. G.H.Dobney, O.H.Belam The scope of nerve root block in physical medicine. Proc R Soc Med. 1963;56:444–6.• Early paper defined the utility of sodium channel blockers in analgesia and medicine.
3. J.J.Bonica. Management of pain with regional analgesia. Postgrad Med J. 1984;60(710):897–904.
4. J.Fritz, A.Chhabra, K.C.Wang, et al. Magnetic resonance neurography-guided nerve blocks for the diagnosis and treatment of chronic pelvic pain syndrome. Neuroimaging Clin N Am. 2014;24(1):211–234.
5. N.Eijkelkamp, J.E.Linley, M.D.Baker, et al. Neurological perspectives on voltage-gated sodium channels. Brain. 2012;135(Pt 9):2585–2612.
6. v1.9: a sodium channel linked to human pain. Nat Rev Neurosci. 2015;16(9):511–519.
7. v1.9 channel mutant. Nat Commun. 2015;6:10049.
8. J.N.Wood, M.Baker. Voltage-gated sodium channels. Curr Opin Pharmacol. 2001;1(1):17–21.
9. N.Ogata, Y.Ohishi. Molecular diversity of structure and function of the voltage-gated Na+ channels. Jpn J Pharmacol. 2002;88(4):365–377.
10. S.P.H.Alexander, A.Mathie, J.A.Peters. Guide to receptors and channels (GRAC), 4th edition. Br J Pharmacol. 2009;158:S1–S239.
11. G.Lees, E.Shipton. Voltage-gated sodium channels in nociception and their potential as targets for new drugs in treatment of chronic neuropathic pain. Curr Anaesthesia Crit Care. 2009;20(5–6):204–208.
12. R.G.Vickery, S.M.Amagasu, R.Chang, et al. Comparison of the pharmacological properties of rat Na(V)1.8 with rat Na(V)1.2a and human Na(V)1.5 voltage-gated sodium channel subtypes using a membrane potential sensitive dye and FLIPR. Recept Channels. 2004;10(1):11–23.
13. M.A.Nassar, L.C.Stirling, G.Forlani, et al. Nociceptor-specific gene deletion reveals a major role for Nav1.7 (PN1) in acute and inflammatory pain. Proc Natl Acad Sci U S A. 2004;101(34):12706–12711.
14. B.Abrahamsen, J.Zhao, C.O.Asante, et al. The cell and molecular basis of mechanical, cold, and inflammatory pain. Science. 2008;321(5889):702–705.
15. Y.Yang, Y.Wang, S.Li, et al. Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia. J Med Genet. 2004;41(3):171–174.• The first link between Nav1.7 and human pain.
16. T.R.Cummins, S.D.Dib-Hajj, S.G.Waxman. Electrophysiological properties of mutant Nav1.7 sodium channels in a painful inherited neuropathy. J Neurosci. 2004;24(38):8232–8236.
17. S.G.Waxman. Painful Na-channelopathies: an expanding universe. Trends Mol Med. 2013;19(7):406–409.
18. C.R.Fertleman, M.D.Baker, K.A.Parker, et al. SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes. Neuron. 2006;52(5):767–774.
19. M.Estacion, T.P.Harty, J.-S.Choi, et al. A sodium channel gene SCN9A polymorphism that increases nociceptor excitability. Ann Neurol. 2009;66(6):862–866.
20. J.W.Theile, B.W.Jarecki, A.D.Piekarz, et al. Nav1.7 mutations associated with paroxysmal extreme pain disorder, but not erythromelalgia, enhance Navbeta4 peptide-mediated resurgent sodium currents. J Physiol. 2011;589(Pt 3):597–608.
21. M.Eberhardt, J.Nakajima, A.B.KLinger, et al. Inherited pain: sodium channel Nav1.7 A1632T mutation causes erythromelalgia due to a shift of fast inactivation. J Biol Chem. 2014;289(4):1971–1980.
22. E.C.Emery, A.M.Habib, J.J.Cox, et al. Novel SCN9A mutations underlying extreme pain phenotypes: unexpected electrophysiological and clinical phenotype correlations. J Neurosci. 2015;35(20):7674–7681.
23. J.J.Cox, F.Reimann, A.K.Nicholas, et al. An SCN9A channelopathy causes congenital inability to experience pain. Nature. 2006;444(7121):894–8.•• A key paper in focusing Pharma attention on Nav1.7 as an analgesic drug target.
24. S.Sun, C.J.Cohen, C.M.Dehnhardt. Inhibitors of voltage-gated sodium channel Nav1.7: patent applications since 2010. Pharm Pat Anal. 2014;3(5):509–521.
25. Convergence Pharmaceuticals, C., UK. Convergence Pharmaceuticals’ Novel Nav1.7 Selective Sodium Channel Blocker CNV1014802 Demonstrates Proof of Concept in Second Neuropathic Pain Study in Lumbosacral Radiculopathy. [updated 2014 Sep 23; [cited Jan, 2016] Available from: http://www.convergencepharma.com/userfiles/file/140923_LSR_FINAL.pdf.
26. Convergence Pharmaceuticals, C., UK. CNV1014802. 2016 [cited 2016 Jan] Available from: http://www.convergencepharma.com/index.asp?page_id=14.
27. Convergence Pharmaceuticals, C., UK. Convergence pharmaceuticals receives orphan-drug designation for Nav1.7 blocking pain drug CNV1014802. [updated Jul 30 2013; [cited 2016 Jan] Available from: http://www.convergencepharma.com/userfiles/file/Orphan%20Drug%20Designation_Final.pdf.
28. Convergence Pharmaceuticals, C., UK. The Pipeline. 2016 [cited 2016 Jan] Available from: http://www.convergencepharma.com/?page_id=16.
29. Convergence Pharmaceuticals, C., UK. A Phase I ready novel sodium channel blocker CNV1061436 for CNS disorders is added to the pipeline of clinical development candidates. [updated 2013 Oct 29; cited 2016 Jan] Available from: http://www.convergencepharma.com/userfiles/file/131029%20Convergence_%20436%20press%20release%20final%20complete.pdf.
30. v1.7 selective blocker with broad anti-hyperalgesic efficacy). 8th Congress of the European Federation of IASP Chapters (EFIC) - Pain in Europe V; 2013 Oct 9–12; Florence, Italy. 2016; http://www.convergencepharma.com/index.asp?page_id=29 [cited 2016 Jan].
31. Xenon Pharmaceuticals Inc., V., Canada. Xenon’s XEN402 ointment significantly relieves pain in patients with post herpetic neuralgia. [updated 2011 May 2;cited 2016 Jan]. Available from: http://www.xenon-pharma.com/2011/05/xenon%E2%80%99s-xen402-ointment-significantly-relieves-pain-in-patients-with-post-herpetic-neuralgia/.
32. Xenon Pharmaceuticals Inc., V., Canada. TV-45070 for the treatment of pain. 2015 [cited 2016 Jan] Available from: http://www.xenon-pharma.com/product-candidates/pain/pain-teva/.
33. Genentech. Pipeline. 2016 [cited 2016 Jan] Available from: http://www.gene.com/medical-professionals/pipeline.
34. AdisInsight Adis International Ltd, p.o.S.S.B.M. Drug Profile (GDC-0310). 2016 [cited 2016 Jan] Available from: http://adisinsight.springer.com/drugs/800043573.
35. Dainippon Sumitomo Pharma Co., L. Supplementary financial data for the third quarter of the year ending March 31, 2013. [updated 2013 Jan 31; cited 2016 January]. Available from: http://www.ds-pharma.com/pdf_view.php?id=278.
36. H.Gursahani, G.Kim, K.Gogas, et al. NKTR-171: A novel sodium channel blocker for neuropathic pain with reduced CNS side effects. Abstract # 8106/ Poster #JJ11: Presented at the Society for Neuroscience 42nd Annual Meeting: Neuroscience 2012; 2012 Oct 13–17; New Orleans, LA. [cited 2012 Oct13–17].
37. Chromocell Corporation, N.B.T., USA. Analgesia program. 2016 [cited 2016 January]. Available from: http://www.chromocell.com/index2.php?sprache=eng&nav=therapeutics&unternav=therapeutics_programs&intern=therapeutics_programs.
38. M.De Lera Ruiz, R.L.Kraus. Voltage-gated sodium channels: structure, function, pharmacology, and clinical indications. J Med Chem. 2015;58(18):7093–7118.
39. D.W.Wheeler, M.C.Lee, E.K.Harrison, et al. Case report: neuropathic pain in a patient with congenital insensitivity to pain [version 2; referees: 2 approved]. F1000Research. 2015;3(135).• Some pains occur in Nav1.7 null humans, a situation that also occurs in Nav1.7 null mice. This supports the existence of multiple peripheral pain mechanisms.
40. v1.7 channel voltage sensor for pain and itch relief. Cell. 2014;157(6):1393–1404.
41. H.Dehen, J.C.Willer, S.Prier, et al. Congenital insensitivity to pain and the “morphine-like” analgesic system. Pain. 1978;5(4):351–358.
42. M.S.Minett, V.Pereira, S.Sikandar, et al. Endogenous opioids contribute to insensitivity to pain in humans and mice lacking sodium channel Nav1.7. Nat Commun. 2015;6:8967.•• A possible explanation for the failure of specific Nav1.7 blockers to replicate a CIP phenotype.
43. M.S.Minett, N.Eijkelkamp, J.N.Wood. Significant determinants of mouse pain behaviour. PLoS One. 2014;9(8):e104458.
44. M.S.Minett, M.A.Nassar, A.K.Clark, et al. Distinct Nav1.7-dependent pain sensations require different sets of sensory and sympathetic neurons. Nat Commun. 2012;3:791.
45. H.Poras, E.Bonnard, E.Dangé, et al. New orally active dual enkephalinase inhibitors (DENKIs) for central and peripheral pain treatment. J Med Chem. 2014;57(13):5748–5763.
46. H.Miyakawa, S.K.Woo, S.C.Dahl, et al. Tonicity-responsive enhancer binding protein, a rel-like protein that stimulates transcription in response to hypertonicity. Proc Natl Acad Sci U S A. 1999;96(5):2538–2542.
47. A.N.Akopian, V.Souslova, S.England, et al. The tetrodotoxin-resistant sodium channel SNS has a specialized function in pain pathways. Nat Neurosci. 1999;2(6):541–8.• The first mouse sodium channel knock-out with a loss of pain phenotype.
48. M.A.Nassar, A.Levato, L.C.Stirling, et al. Neuropathic pain develops normally in mice lacking both Na(v)1.7 and Na(v)1.8. Molecular Pain. 2005;1:24.
49. K.Zimmermann, A.Leffler, A.Babes, et al. Sensory neuron sodium channel Nav1. 8 is essential for pain at low temperatures. Nature. 2007;447(7146):856–859.
50. A.Bierhaus, T.Fleming, S.Stoyanov, et al. Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. Nat Med. 2012;18(6):926–933.
51. C.G.Faber, G.Lauria, I.S.Merkies, et al. Gain-of-function Nav1.8 mutations in painful neuropathy. Proc Natl Acad Sci U S A. 2012;109(47):19444–19449.
52. J.Huang, Y.Yang, P.Zhao, et al. Small-fiber neuropathy Nav1.8 mutation shifts activation to hyperpolarized potentials and increases excitability of dorsal root ganglion neurons. J Neurosci. 2013;33(35):14087–14097.
53. v1.8 mutation in small fibre neuropathy: impaired inactivation underlying DRG neuron hyperexcitability. J Neurol Neurosurg Psychiatry. 2014;85(5):499–505.
54. J.C.Chambers, J.Zhao, C.M.Terracciano, et al. Genetic variation in SCN10A influences cardiac conduction. Nat Genet. 2010;42(2):149–152.
55. S.K.Bagal, P.J.Bungay, S.M.Dentom, et al. Discovery and optimization of selective Nav1.8 modulator series that demonstrate efficacy in preclinical models of pain. ACS Med Chem Lett. 2015;6(6):650–654.
56. A.O.Verkerk, C.A.Remme, C.A.Schumacher, et al. Functional Nav1.8 channels in intracardiac neurons: the link between SCN10A and cardiac electrophysiology. Circ Res. 2012;111(3):333–343.
57. H.Holm, D.F.Gudbjartsson, D.O.Arnar, et al. Several common variants modulate heart rate, PR interval and QRS duration. Nat Genet. 2010;42(2):117–122.
58. N.Sotoodehnia, A.Isaacs, P.I.De Bakker, et al. Common variants in 22 loci are associated with QRS duration and cardiac ventricular conduction. Nat Genet. 2010;42(12):1068–1076.
59. A.Pfeufer, C.Van Noord, K.D.Marciante, et al. Genome-wide association study of PR interval. Nat Genet. 2010;42(2):153–159.
60. T.Yang, T.C.Atack, D.M.Stroud, et al. Blocking Scn10a channels in heart reduces late sodium current and is antiarrhythmic. Circ Res. 2012;111(3):322–332.
61. S.Lolignier, M.Amsalem, F.Maingret, et al. Nav1.9 channel contributes to mechanical and heat pain hypersensitivity induced by subacute and chronic inflammation. PLoS One. 2011;6(8):e23083.
62. S.Leo, R.D’Hooge, T.Meert. Exploring the role of nociceptor-specific sodium channels in pain transmission using Nav1.8 and Nav1.9 knockout mice. Behav Brain Res. 2010;208(1):149–157.
63. v1.9 to sensory transmission and nociceptive behavior. Proc Natl Acad Sci U S A. 2005;102(26):9382–9387.
64. F.Amaya, H.Wang, M.Costigan, et al. The voltage-gated sodium channel Na(v)1.9 is an effector of peripheral inflammatory pain hypersensitivity. J Neurosci. 2006;26(50):12852–12860.
65. K.Hillsley, J.H.Lim, A.Stanisz, et al. Dissecting the role of sodium currents in visceral sensory neurons in a model of chronic hyperexcitability using Nav1.8 and Nav1.9 null mice. J Physiol. 2006;576(Pt 1):257–267.
66. A.A.Sleeper, T.R.Cummins, S.D.Dib-Hajj, et al. Changes in expression of two tetrodotoxin-resistant sodium channels and their currents in dorsal root ganglion neurons after sciatic nerve injury but not rhizotomy. J Neurosci. 2000;20(19):7279–7289.
67. A.P.Luiz, O.Kopach, S.Santana-Varela, et al. The role of Na1.9 channel in the development of neuropathic orofacial pain associated with trigeminal neuralgia. Mol Pain. 2015;11(1):72.
68. J.Huang, C.Han, M.Estacion, et al. Gain-of-function mutations in sodium channel Na(v)1.9 in painful neuropathy. Brain. 2014;137(Pt 6):1627–1642.
69. X.Y.Zhang, J.Wen, W.Yang, et al. Gain-of-function mutations in SCN11A cause familial episodic pain. Am J Hum Genet. 2013;93(5):957–966.
70. C.Han, Y.Yang, B.T.De Greef, et al. The domain II S4-S5 linker in Nav1.9: a missense mutation enhances activation, impairs fast inactivation, and produces human painful neuropathy. Neuromolecular Med. 2015;17(2):158–169.
71. E.Leipold, L.Leibmann, G.C.Korenke, et al. A de novo gain-of-function mutation in SCN11A causes loss of pain perception. Nat Genet. 2013;45(11):1399–1404.
72. W.J.Brackenbury. Voltage-gated sodium channels and metastatic disease. Channels (Austin). 2012;6(5):352–361.
73. K.H.Jansson, D.G.Castillo, J.W.Morris, et al. Identification of beta-2 as a key cell adhesion molecule in PCa cell neurotropic behavior: a novel ex vivo and biophysical approach. PLoS One. 2014;9(6):e98408.
74. L.Brisson, L.Gillet, S.Calaghan, et al. Na(V)1.5 enhances breast cancer cell invasiveness by increasing NHE1-dependent H(+) efflux in caveolae. Oncogene. 2011;30(17):2070–2076.
75. L.Brisson, S.J.Reshkin, J.Gore, et al. pH regulators in invadosomal functioning: proton delivery for matrix tasting. Eur J Cell Biol. 2012;91(11–12):847–860.
76. A.Morinville, B.Fundin, L.Meury, et al. Distribution of the voltage-gated sodium channel Na(v)1.7 in the rat: expression in the autonomic and endocrine systems. J Comp Neurol. 2007;504(6):680–689.
77. S.D.Dib-Hajj, Y.Yang, J.A.Black, et al. The Na(V)1.7 sodium channel: from molecule to man. Nat Rev Neurosci. 2013;14(1):49–62.
78. v1.7: stress-induced changes in immunoreactivity within magnocellular neurosecretory neurons of the supraoptic nucleus. Mol Pain. 2013;9:39.
79. J.Weiss, M.Pyrski, E.Jacobi, et al. Loss-of-function mutations in sodium channel Nav1.7 cause anosmia. Nature. 2011;472(7342):186–190.
80. K.Salat, P.Kowalczyk, B.Gryzio, et al. New investigational drugs for the treatment of neuropathic pain. Expert Opin Investig Drugs. 2014;23(8):1093–1104.
81. ClinicalTrial.gov (A service of the U.S. National Institutes of Health). Safety & efficacy study of subcutaneous tetrodotoxin for moderate to severe inadequately controlled cancer-related pain (TEC-006). [updated 2016 Jan 04; cited 2016 Jan]. Available from: https://www.clinicaltrials.gov/ct2/show/nct00725114.
82. C.Le Guiner, K.Stieger, A.Toromanoff, et al. Transgene regulation using the tetracycline-inducible TetR-KRAB system after AAV-mediated gene transfer in rodents and nonhuman primates. PLoS One. 2014;9(9).
83. D.Katzel, E.Nicholson, S.Schorge, et al. Chemical-genetic attenuation of focal neocortical seizures. Nat Commun. 2014;5:3847.• A tour de force of gene therapy regulation of neuronal excitability that could be applied to pain.
84. J.Koenig, R.Werdehausen, J.E.Linley, et al. Regulation of Nav1.7: a conserved SCN9A natural antisense transcript expressed in dorsal root ganglia. PLoS One. 2015;10(6):e0128830.